Dallas, TX -- (SBWIRE) -- 03/12/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
Tupperware Brands Corporation (NYSE:TUP) went down 3.97% and closed at $76.10 on a traded volume of 1.45 million shares. Morgan Stanley lowered the rating on Tupperware to equal-weight from overweight. The rating was lowered for the direct seller of plastic storage containers and personal care products, partly because of its stock price.
Is TUP a Strong Buy After The Recent Gain? Let’s Find out Here
Trina Solar Limited (ADR) (NYSE:TSL) declined 3.33% and closed at $4.07. The median Wall Street price target on the stock is $4.50 and the high target is set at $10.00 with majority of analysts have a hold rating on the company’s stock. The stock has the 50- Day Moving Average and 200-Day Moving Average prices of $4.80 and $4.29 respectively.
Is TSL a Strong Buying Opportunity After The Recent Slump? Find out Here
MetroPCS Communications Inc. (NYSE:PCS) slipped 2.87% and closed at $10.50 on a traded volume of 5.53 million shares. MetroPCS Communications announced that MetroPCS Wireless, Inc. an indirect wholly-owned subsidiary has agreed to sell $1,750,000,000 aggregate principal amount of its 6.250% Senior Notes due 2021 and $1,750,000,000 aggregate principal amount of its 6.625% Senior Notes due 2023 in a private offering. The offering is scheduled to close on March 19, 2013, subject to satisfaction of customary closing conditions. Wireless will deposit the net proceeds of this offering into a segregated account and keep such net proceeds on hand at all times in cash or cash equivalents.
Should Investors Consider PCS After The Recent price Action? Get Free Trend Analysis Here
Edwards Lifesciences Corp (NYSE:EW) slipped 2.47% and closed at $88.07 on a traded volume of 1.74 million shares. Edwards Lifesciences Corp. said that patients who were implanted with its new Sapien XT heart valve did about as well as patients who received an older version of the valve. Edwards said the rates of death and stroke among the two groups of patients were similar. However the rate of "vascular events" was lower in patients who had the Sapien XT valve. The results came from an ongoing clinical trial, and Edwards plans to submit them to the Food and Drug Administration as it seeks marketing approval for Sapien XT.
Should Investors Consider EW After The Recent price Action? Get Free Trend Analysis Here
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)